These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 34613513)

  • 1. Methylphenidate Improves Autonomic Functioning among Youth with Attention-Deficit/Hyperactivity Disorder.
    Morris SSJ; Musser ED; Tenenbaum RB; Ward AR; Raiker JS; Coles EK
    Res Child Adolesc Psychopathol; 2022 May; 50(5):591-603. PubMed ID: 34613513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emotion Regulation via the Autonomic Nervous System in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Replication and Extension.
    Morris SSJ; Musser ED; Tenenbaum RB; Ward AR; Martinez J; Raiker JS; Coles EK; Riopelle C
    J Abnorm Child Psychol; 2020 Mar; 48(3):361-373. PubMed ID: 31808007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents.
    Soutullo C; Banaschewski T; Lecendreux M; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Bloomfield R; Squires LA; Coghill DR
    CNS Drugs; 2013 Sep; 27(9):743-51. PubMed ID: 23801529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OROS-methylphenidate efficacy on specific executive functioning deficits in adults with ADHD: a randomized, placebo-controlled cross-over study.
    Bron TI; Bijlenga D; Boonstra AM; Breuk M; Pardoen WF; Beekman AT; Kooij JJ
    Eur Neuropsychopharmacol; 2014 Apr; 24(4):519-28. PubMed ID: 24508533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
    Su Y; Yang L; Stein MA; Cao Q; Wang Y
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential impact of methylphenidate and atomoxetine on sustained attention in youth with attention-deficit/hyperactivity disorder.
    Bédard AC; Stein MA; Halperin JM; Krone B; Rajwan E; Newcorn JH
    J Child Psychol Psychiatry; 2015 Jan; 56(1):40-8. PubMed ID: 24942409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder.
    Wolraich ML; Greenhill LL; Pelham W; Swanson J; Wilens T; Palumbo D; Atkins M; McBurnett K; Bukstein O; August G
    Pediatrics; 2001 Oct; 108(4):883-92. PubMed ID: 11581440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remission in children and adolescents diagnosed with attention-deficit/hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate.
    Chou WJ; Chen SJ; Chen YS; Liang HY; Lin CC; Tang CS; Huang YS; Yeh CB; Chou MC; Lin DY; Hou PH; Wu YY; Liu HJ; Huang YF; Hwang KL; Chan CH; Pan CH; Chang HL; Huang CF; Hsu JW
    J Child Adolesc Psychopharmacol; 2012 Jun; 22(3):215-25. PubMed ID: 22537358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Academic, behavioral, and cognitive effects of OROS® methylphenidate on older children with attention-deficit/hyperactivity disorder.
    Wigal SB; Wigal T; Schuck S; Brams M; Williamson D; Armstrong RB; Starr HL
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):121-31. PubMed ID: 21488750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of osmotic-controlled release oral delivery system methylphenidate HCl in adults with attention-deficit/hyperactivity disorder in Japan.
    Takahashi N; Koh T; Tominaga Y; Saito Y; Kashimoto Y; Matsumura T
    World J Biol Psychiatry; 2014 Aug; 15(6):488-98. PubMed ID: 24456065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Individualized, Data-Driven Biological Approach to Attention-Deficit/Hyperactivity Disorder (ADHD) Heterogeneity.
    Morris SSJ; Timmons A; Musser ED
    Res Child Adolesc Psychopathol; 2023 Nov; 51(11):1565-1579. PubMed ID: 37542616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders.
    Riggs PD; Winhusen T; Davies RD; Leimberger JD; Mikulich-Gilbertson S; Klein C; Macdonald M; Lohman M; Bailey GL; Haynes L; Jaffee WB; Haminton N; Hodgkins C; Whitmore E; Trello-Rishel K; Tamm L; Acosta MC; Royer-Malvestuto C; Subramaniam G; Fishman M; Holmes BW; Kaye ME; Vargo MA; Woody GE; Nunes EV; Liu D
    J Am Acad Child Adolesc Psychiatry; 2011 Sep; 50(9):903-14. PubMed ID: 21871372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebo-controlled trial.
    Winhusen TM; Somoza EC; Brigham GS; Liu DS; Green CA; Covey LS; Croghan IT; Adler LA; Weiss RD; Leimberger JD; Lewis DF; Dorer EM
    J Clin Psychiatry; 2010 Dec; 71(12):1680-8. PubMed ID: 20492837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder.
    Weisler RH; Pandina GJ; Daly EJ; Cooper K; Gassmann-Mayer C;
    CNS Drugs; 2012 May; 26(5):421-34. PubMed ID: 22519922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evaluation of the effect of methylphenidate on working memory, time perception, and choice impulsivity in children with ADHD.
    Campez M; Raiker JS; Little K; Altszuler AR; Merrill BM; Macphee FL; Gnagy EM; Greiner AR; Musser ED; Coles EK; Pelham WE
    Exp Clin Psychopharmacol; 2022 Apr; 30(2):209-219. PubMed ID: 33475395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of MPH-OROS on the organizational, time management, and planning behaviors of children with ADHD.
    Abikoff H; Nissley-Tsiopinis J; Gallagher R; Zambenedetti M; Seyffert M; Boorady R; McCarthy J
    J Am Acad Child Adolesc Psychiatry; 2009 Feb; 48(2):166-75. PubMed ID: 19127171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subjective effects, misuse, and adverse effects of osmotic-release methylphenidate treatment in adolescent substance abusers with attention-deficit/hyperactivity disorder.
    Winhusen TM; Lewis DF; Riggs PD; Davies RD; Adler LA; Sonne S; Somoza EC
    J Child Adolesc Psychopharmacol; 2011 Oct; 21(5):455-63. PubMed ID: 22040190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Clinical Trial of ORADUR-Methylphenidate for Treating Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
    Huang YS; Yeh CB; Chen CH; Shang CY; Gau SS
    J Child Adolesc Psychopharmacol; 2021 Apr; 31(3):164-178. PubMed ID: 33395356
    [No Abstract]   [Full Text] [Related]  

  • 20. Seasonal Patterns of Medications for Treating Attention-Deficit/Hyperactivity Disorder: Comparison of Methylphenidate and Atomoxetine.
    Shyu YC; Lee SY; Yuan SS; Yang CJ; Yang KC; Lee TL; Wang LJ
    Clin Ther; 2016 Mar; 38(3):595-602. PubMed ID: 26874787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.